Acknowledgements and Funding
The authors thank and acknowledge the consent and cooperation of all ONDRI participants. Many thanks to the ONDRI investigators (lead investigator: Michael Strong) and the ONDRI governing committees: executive committee; steering committee; publication committee; recruiting clinicians; assessment platforms leaders; and the ONDRI project management team. For a full list of the ONDRI investigators, please visit: www.ONDRI.ca/people.
The ONDRI project is funded by the Ontario Brain Institute through the Government of Ontario with matching funds provided by participating hospital and research institute foundations, including the Baycrest Foundation, Bruyère Research Institute, Centre for Addiction and Mental Health Foundation, London Health Sciences Foundation, McMaster University Faculty of Health Sciences, Ottawa Brain and Mind Research Institute, Queen’s University Faculty of Health Sciences, Providence Care (Kingston), Sunnybrook Health Sciences Foundation, the Thunder Bay Regional Health Sciences Centre, the University of Ottawa Faculty of Medicine, and the Windsor/Essex County ALS Association. The Temerty Family Foundation provided the major infrastructure matching funds. SMKF is supported by the Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarship. RHS receives salary support from the Heart and Stroke Foundation of Canada New Investigator and Henry J.M. Barnett Awards, the L.C. Campbell Research Chair. and the Canadian Partnership for Stroke Recovery.
Statement of Authorship
RB, SEB, DC, EF, MF, BG, DAG, RAH, CH, PWK, AEL, MM, PMM, MM-O, DGM, DPM, S. Strother, RHS, S. Symons, MCT, LZ, and MJS conceived and designed the study. SMKF, RB, SEB, DC, EF, MF, BG, DAG, RAH, CH, PWK, AEL, MM, PMM, MM-O, DGM, DPM, S. Strother, RHS, S. Symons, MCT, LZ, and MJS prepared the manuscript. MJS was the study lead investigator.
The authors do not have anything to disclose.
WHO takes up the baton on dementia. Lancet Neurol. 2015;14:455.
Herrmann, N, Harimoto, T, Balshaw, R, Lanctot, KL. Risk factors for progression of Alzheimer Disease in a Canadian population: the Canadian Outcomes Study in Dementia (COSID). Can J Psychiatry. 2015;60:189-199.
Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280-292.
Gomersall, T, Astell, A, Nygard, L, Sixsmith, A, Mihailidis, A, Hwang, A. Living with ambiguity: a metasynthesis of qualitative research on mild cognitive impairment. Gerontologist. 2015;55:892-912.
Strong, MJ, Grace, GM, Freedman, M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:131-146.
Woolley, SC, Strong, MJ. Frontotemporal dysfunction and dementia in amyotrophic lateral sclerosis. Neurol Clin. 2015;33:787-805.
Dorsey, ER, Constantinescu, R, Thompson, JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384-386.
Aarsland, D, Zaccai, J, Brayne, C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20:1255-1263.
Hely, MA, Reid, WG, Adena, MA, Halliday, GM, Morris, JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837-844.
Kertesz, A. Frontotemporal dementia/Pick’s disease. Arch Neurol. 2004;61:969-971.
Saposnik, G, Cote, R, Rochon, PA, et al. Care and outcomes in patients with ischemic stroke with and without preexisting dementia. Neurology. 2011;77:1664-1673.
Saposnik, G, Black, SE, Hakim, A, Fang, J, Tu, JV, Kapral, MK. Age disparities in stroke quality of care and delivery of health services. Stroke. 2009;40:3328-3335.
Pendlebury, ST, Mariz, J, Bull, L, Mehta, Z, Rothwell, PM. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke. 2012;43:464-469.
Hachinski, V, Iadecola, C, Petersen, RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220-2241.
Montero-Odasso, M, Casas, A, Hansen, KT, et al. Quantitative gait analysis under dual-task in older people with mild cognitive impairment: a reliability study. J Neuroeng Rehabil. 2009;6:35.
Montero-Odasso, M, Muir, SW, Speechley, M. Dual-task complexity affects gait in people with mild cognitive impairment: the interplay between gait variability, dual tasking, and risk of falls. Arch Phys Med Rehabil. 2012;93:293-299.
Ghani, M, Lang, AE, Zinman, L, et al. Mutation analysis of patients with neurodegenerative disorders using NeuroX array. Neurobiol Aging. 2015;36(545):e549-514.
Ballard, CG, Morris, CM, Rao, H, et al. APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology. 2004;63:1399-1402.
Tsuang, D, Leverenz, JB, Lopez, OL, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70:223-228.
Xi, Z, Zinman, L, Grinberg, Y, et al. Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol. 2012;69:1583-1590.
Friedman, L, Stern, H, Brown, GG, Mathalon, DH, Turner, J, Glover, GH, et al. Test-retest and between-site reliability in a multicenter fMRI study. Hum Brain Mapp. 2008;29:958-972.
Nestor, SM, Gibson, E, Gao, FQ, Kiss, A, Black, SE. A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer’s disease. Neuroimage. 2013;66:50-70.
Nestor, SM, Rupsingh, R, Borrie, M, et al. Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain. 2008;131:2443-2454.
Dade, LA, Gao, FQ, Kovacevic, N, et al. Semiautomatic brain region extraction: a method of parcellating brain regions from structural magnetic resonance images. Neuroimage. 2004;22:1492-1502.
Ramirez, J, Gibson, E, Quddus, A, et al. Lesion Explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. Neuroimage. 2011;54:963-973.
Wahlund, LO, Julin, P, Lindqvist, J, Scheltens, P. Visual assessment of medical temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Res. 1999;90:193-199.
Scheltens, P, Leys, D, Barkhof, F, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967-972.
Fazekas, F, Chawluk, JB, Alavi, A, Hurtig, HI, Zimmerman, RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351-356.
Scheltens, P, Barkhof, F, Leys, D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993;114:7-12.
Cordonnier, C, Potter, GM, Jackson, CA, et al. improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). Stroke. 2009;40:94-99.
Holmes, C, Boche, D, Wilkinson, D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-223.
Iadecola, C, Anrather, J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci. 2011;14:1363-1368.
Lang, AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med. 2010;16:1223-1226.
Farhan, SM, Dilliott, AA, Ghani, M, et al. The ONDRISeq panel: custom designed next generation sequencing of genes related to neurodegeneration. Genom Med. 2016; Article number 16032;doi:10.1038/npjgenmed.2016.32.